Ligand Pharmaceuticals Files 8-K Current Report
Ticker: LGNZZ · Form: 8-K · Filed: Apr 17, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
Related Tickers: LGND
TL;DR
LGND filed an 8-K on 4/17 for an event on 4/16 - standard disclosure, check for details.
AI Summary
Ligand Pharmaceuticals Inc. filed an 8-K on April 17, 2025, reporting an event on April 16, 2025. The filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a disclosure under Regulation FD and the filing of financial statements and exhibits. No specific financial transactions or material events are detailed in the provided text.
Why It Matters
This filing indicates Ligand Pharmaceuticals is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Registrant
- 0000886163-25-000020 (filing_id) — Accession Number
- 20250416 (date) — Earliest event reported
- 20250417 (date) — Filing date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to serve as a Current Report under Section 13 or 15(d) of the Securities Exchange Act of 1934, disclosing events occurring on or before April 16, 2025.
What specific event triggered this 8-K filing?
The filing indicates an event date of April 16, 2025, and it is being filed as of April 17, 2025, but the specific triggering event is not detailed in the provided text.
What are the key identifiers for Ligand Pharmaceuticals Inc. in this filing?
Ligand Pharmaceuticals Inc. is identified by its Commission File Number 001-33093 and its I.R.S. Employer Identification No. 77-0160744.
Where are Ligand Pharmaceuticals Inc.'s principal executive offices located?
Ligand Pharmaceuticals Inc.'s principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
What items are being reported in this 8-K filing?
The filing indicates Item Information for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).